How IBD treatment works

The goal of treatment, the main groups of IBD medicines, biosimilars, surgery, food and smoking, explained in plain words.

Reviewed October 2026 8 min read

At a glance

  • The goal is to calm the inflammation, not just the symptoms. Your team checks with stool, blood and bowel tests.
  • Keep taking your medicine when you feel well. Stopping can bring back a flare.
  • Steroids (like prednisone) are for short-term use only. Never stop them suddenly. Follow the taper your team gives you.
  • If a medicine is not working well enough after a fair trial, ask about other options. There are many.
  • A biosimilar works the same way as the original biologic. Many people in Canada have switched safely.
  • Surgery is a good treatment for some people. It is not a failure.
  • If you smoke, quitting is one of the best things you can do for Crohn's disease. Ask for help to quit.
  • Before you start or change any medicine, supplement or diet, check with your IBD team or pharmacist.

The goal: calm the inflammation

Feeling better is important. But in IBD, feeling well is not the whole goal. Inflammation can still be there when you feel fine, and over time it can harm the bowel.

So your team aims for clear goals and checks that you reach them. Doctors call this “treat to target.” In plain words:

  1. Short term

    You feel well

    Your bowel habits are back to normal for you, with no blood and little pain.
  2. Short term

    Your tests are normal

    Blood and stool tests show no sign of inflammation.
  3. Long term

    Your bowel has healed

    A scope or scan shows the lining has healed.
  4. Long term

    You can live your life

    Work, school, sleep and family life are not held back by IBD.

If a target is not reached, your team may change the dose, add a medicine, or switch to a new one. Read How we check on your IBD to learn about the tests.

The main types of IBD medicine

Your team will suggest a plan based on the type of IBD you have, where it is, how active it is, and what matters to you. Many people need more than one medicine at some point.

The main groups of IBD medicine
Group Examples How it is taken
5-ASA mesalamine, sulfasalazine Pills, granules, suppositories or enemas
Steroids prednisone, budesonide Pills, IV in hospital, or rectal forms
Immuno­modulators azathioprine, mercaptopurine, methotrexate Pills. Methotrexate can be a weekly shot
Biologics infliximab, adalimumab, vedolizumab, ustekinumab and others (see below) IV drip in a clinic, or a shot under the skin
Advanced pills tofacitinib, upadacitinib, ozanimod, etrasimod Pills by mouth

Biologics and advanced pills are mainly used for moderate to severe IBD. Tofacitinib, ozanimod and etrasimod are for ulcerative colitis. Upadacitinib is used for both.

If your IBD is moderate to severe, you may not need to try the older medicines first. Newer guidelines advise starting a biologic or advanced pill early for many people. Ask your team which plan fits you.

5-ASA

5-ASA medicines calm inflammation in the lining of the colon. They are the first choice for mild to moderate ulcerative colitis. They are not usually used for Crohn’s disease, because they don’t work well for it.

Steroids are for short-term use

Steroids such as prednisone work fast. They can calm a flare in days to weeks. But they are not used to keep IBD calm over the long term. Long use can thin your bones and cause other side effects. The aim is always to be well without steroids.

Immunomodulators

These medicines calm the immune system. They help keep IBD quiet, and they are sometimes taken with a biologic so it works better. You will need regular blood tests, especially in the first months. Methotrexate must not be used if you are trying to get pregnant.

Biologics and advanced pills

These are often called advanced therapy. Each one blocks a different signal that drives inflammation:

  • Anti-TNF: infliximab, adalimumab, golimumab
  • Gut-focused (anti-integrin): vedolizumab
  • IL-12/23 and IL-23 blockers: ustekinumab, risankizumab (Skyrizi), mirikizumab (Omvoh), guselkumab (Tremfya). All four are approved in Canada for both Crohn’s and colitis.
  • JAK inhibitors (pills): tofacitinib, upadacitinib
  • S1P modulators (pills): ozanimod, etrasimod

Some are given as an IV drip in a clinic. Some are shots you give yourself at home. Some are pills. There are now many choices. If one does not work, there are others to try. Read Starting a biologic or advanced pill to learn what to expect.

Biosimilars

A biosimilar is a copy of a biologic medicine. It is made to be highly similar to the original. Health Canada reviews biosimilars to the same strict standards. It expects no real difference in how well they work or how safe they are, even when you switch.

In Canada, there are now biosimilars of infliximab, adalimumab and ustekinumab. Provinces have moved many people from original biologics to biosimilars. In Ontario, people covered by the Ontario Drug Benefit switched from the original infliximab and adalimumab in 2023, and from the original ustekinumab in 2024 to 2025. In some cases, such as pregnancy, people could ask to stay on the original for a time.

Dr. Squirell helped write a review of real-world studies of these switches. People who switched to an infliximab biosimilar did about as well as people who stayed on the original.

Still in remission a year later, on infliximab
  • Switched to a biosimilar75 in 100
  • Stayed on the original78 in 100

From a review of 43 real-world studies with more than 7,400 people with IBD (Meade, Squirell and others, 2024).

Results for adalimumab were also reassuring. Some people found one adalimumab biosimilar stung more when injected.

Your biosimilar may have a different brand name, pen or schedule. Ask your nurse to show you how to use a new pen. If you have private insurance, ask your plan or pharmacist what it covers.

Surgery is a real treatment

Surgery is sometimes the best choice. It is not a sign that you or your treatment failed.

  • Ulcerative colitis: Removing the colon can cure the bowel disease. It is a big decision and is usually not the first step.
  • Crohn’s disease: Surgery doesn’t cure Crohn’s, but it can treat a narrowing (stricture), a blockage, an abscess (pocket of pus), a fistula (tunnel), or disease that medicine can’t control. After surgery, your team will check for signs that Crohn’s is coming back.

If surgery is an option for you, you can meet the surgeon early to ask questions. That is not a promise to have surgery.

What about food?

No single diet cures IBD or works for everyone. Avoid fad diets. Try to eat a balanced diet with enough protein and calories.

  • During a flare, some foods may bother you more. That is OK to adjust for a short time.
  • If you have a narrowing in your bowel, your team may ask you to eat less tough fibre (like nuts, seeds and raw vegetable skins). See Fibre.
  • For some people with Crohn’s, a liquid nutrition plan can be used as treatment.
  • If you are cutting out many foods or losing weight, ask to see a dietitian.

Smoking and Crohn’s disease

If you have Crohn’s disease, smoking makes it worse. People who smoke have more flares and need more medicine.

The good news: quitting helps. In one study, people with Crohn’s who stopped smoking for more than a year had flares about as often as people who never smoked. Ask your family doctor, pharmacist or IBD team for help. Counselling and quit-smoking medicines both work.

Do I have to take medicine forever?

Most people with IBD need long-term medicine to stay well. Some people can lower or stop a medicine after a long time in deep remission, but this has risks. It should only be done with your team. See Thinking about stopping your IBD medicine.

Can I use natural products or cannabis?

Tell your team about everything you take, including vitamins, herbs and cannabis. Some products can affect your other medicines.

Sources for this guide

Sources

  1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the IOIBD. Gastroenterology 2021;160:1570–83. PMID 33359090 Treat to target: short-term targets are symptom relief and normal CRP and calprotectin; long-term targets are endoscopic healing, normal quality of life and no disability.
  2. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035–58. PMID 25747596 Canadian UC guideline: the goal is symptom and endoscopic remission without steroids; 5-ASA is first-line for mild to moderate UC; steroids for induction, not maintenance.
  3. Panaccione R, Steinhart AH, Bressler B, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn's disease. J Can Assoc Gastroenterol 2019;2:e1–e34. PMID 31294378 Against 5-ASA for Crohn's; steroids (including budesonide) for induction but not maintenance; thiopurines and methotrexate for maintenance in selected patients; biologics when conventional therapy fails.
  4. Narula N, Leung Y. Induction of Advanced Therapy clinical care pathway. Crohn's and Colitis Canada PACE IBD Clinical Care Pathways, version January 21, 2026. Advanced therapies used in Canada, their targets and how they are given (IV, under the skin, by mouth).
  5. McCabe Woodrow C, Bollegala N. Initiation of Immunomodulators clinical care pathway. Crohn's and Colitis Canada PACE IBD Clinical Care Pathways, version January 21, 2026. Blood tests weekly for the first month, then monthly for 6 months, then every 3 months; methotrexate is not used when trying to get pregnant; yearly skin checks.
  6. Meade S, Squirell E, Hoang T, Chow L, et al. An update on anti-TNF biosimilar switching: real-world clinical effectiveness and safety. J Can Assoc Gastroenterol 2024;7(1):30–45. PMID 38314175 Systematic review, 43 studies, 7,462 patients: after switching to an infliximab biosimilar, 75% stayed in remission beyond 12 months (78% on the original); for adalimumab, 82% stayed in remission at 6 months. More injection-site pain with a citrate-containing adalimumab biosimilar. Co-authored by Dr. Squirell.
  7. Health Canada. Biosimilar biologic drugs in Canada: fact sheet (page details 2026-05-20). Biosimilars are authorized to the same standards; no expected clinically meaningful differences in efficacy or safety, including after a switch.
  8. Government of Ontario. Biosimilars (Ontario Drug Benefit policy), updated December 15, 2025. ODB recipients moved from originator infliximab and adalimumab to biosimilars (March to December 2023) and from originator ustekinumab (July 2024 to January 2025); exemptions can be requested.
  9. Crohn's and Colitis Canada. Frequently asked questions (accessed October 2026). No standard diet is the solution for IBD; avoid fad diets and eat a balanced diet.
  10. Crohn's and Colitis Canada. What are Crohn's and colitis? (accessed October 2026). Removing the colon may be considered curative for UC; there is no cure for Crohn's.
  11. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Crohn's disease (accessed October 2026). Surgery does not cure Crohn's but treats complications (blockage, fistula, abscess, bleeding) and symptoms that don't improve with medicine.
  12. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001;120:1093–9. PMID 11266373 After quitting for more than a year, flare risk was like that of non-smokers and lower than in people who kept smoking.
  13. Nistor I, Huang V. Health Maintenance clinical care pathway. Crohn's and Colitis Canada PACE IBD Clinical Care Pathways, version January 21, 2026. Strongly advise quitting smoking, especially in Crohn's, with counselling and medicine; avoid restrictive diets without a dietitian; enteral (liquid) nutrition can be used in Crohn's.
  14. West Hertfordshire Teaching Hospitals NHS Trust. Managing a Crohn's or colitis flare-up (patient leaflet, v3, ratified June 2026). Do not start steroid tablets without talking to your IBD team; steroids are reduced over weeks, not stopped suddenly; do not change immunosuppressant or biologic doses without advice.
  15. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 2024;167:1307–43. PMID 39572132 Suggests early use of advanced therapies and/or immunomodulators in moderate to severe UC, rather than gradual step-up after 5-ASA fails.
  16. Scott FI, Ananthakrishnan AN, Click B, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn's disease. Gastroenterology 2025;169:1397–448. PMID 41274746 Suggests initial advanced therapy over step therapy with steroids and/or immunomodulators in moderate to severe Crohn's disease; lists ustekinumab, risankizumab, mirikizumab and guselkumab among recommended agents.
  17. Health Canada. Drug Product Database (accessed October 11, 2026). Marketed in Canada: ustekinumab biosimilars (e.g. Jamteki, Wezlana, Steqeyma, Otulfi, Yesintek, Pyzchiva); new Omvoh (mirikizumab) and Tremfya (guselkumab, including Tremfya I.V.) products marketed 2025 for Crohn's disease.
  18. Eli Lilly Canada. Health Canada approves Omvoh (mirikizumab) for Crohn's disease (news release, July 15, 2025). Omvoh now approved in Canada for both ulcerative colitis and Crohn's disease.
  19. Johnson & Johnson Canada. Health Canada authorizes Tremfya (guselkumab) for Crohn's disease (news release, July 31, 2025). Crohn's disease approval with IV or subcutaneous induction. Health Canada approved Tremfya for ulcerative colitis on September 3, 2025 (CDA-AMC review SR0874).
  20. AbbVie Canada. Skyrizi (risankizumab) now available for moderately to severely active ulcerative colitis (news release, March 4, 2025; reposted by Life Sciences BC). Health Canada approved risankizumab for ulcerative colitis in October 2024; it was already approved for Crohn's disease.
  21. Murthy SK, Weizman AV, Kuenzig ME, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape. J Can Assoc Gastroenterol 2023;6(Suppl 2):S97–S110. PMID 37674501 Earlier use of targeted therapies, combining them with immunomodulators, and treating to objective markers improve outcomes; biosimilars lower costs.
  22. Crohn's and Colitis Canada. Are you at risk? (accessed October 2026). Smoking raises the risk of Crohn's; people who have quit smoking have a higher risk of UC.

This guide is for general education. It can't replace advice from your own care team, who know your health history.

Report a problem with this guide

Please don't include patient information. This form isn't for medical questions.

Try “pregnancy”, “Mayo”, “calprotectin” or “VARSITY”.